Fortress Biotech, Inc. (FBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Fortress Biotech, Inc. (FBIO) closed at USD 1.90 on 2026-10-14, a change of -25.8 % over the past year, with a market capitalization of USD 63.7M.

Fortress Biotech, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Fortress Biotech, Inc. key figures

Previous close

USD 1.90 (2026-10-14)

1-year change

-25.8 %

Market cap

USD 63.7M

Enterprise value

USD -37.61M

P/E ratio (trailing)

0.69

P/E ratio (forward)

-1.09

EPS (trailing)

2.76

EPS (forward)

-1.76

PEG ratio

n/a

Price to book

0.39

Revenue growth

14 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.93

Employees

78

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Fortress Biotech, Inc.

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Fortress Biotech, Inc. and compare it with other stocks.